Zhou N, Jiang M, Li T, Zhu J, et al. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. Lung Cancer 2021;160:111-117.
PMID: 34482102